Positive results show that CTC can be used as a screening tool.
"Fewer people shall die in cancer"
iCellate is portrayed in the DI Life Science theme issue
2 studies in very interesting cohorts will be conducted in collaboration with RCC Stockholm-Gotland
External board elected
WE MOVED IN!
As a Christmas gift 2016, iCellate signs 350 sqm office and lab space in Hagalund
iCellate's CTC isolation device received CE-approval according to the IVD-directive
Karolinska Institutet Science Park Day 2016
iCellate Medical has initiated a project in genetic sequencing
iCellate is happy to announce another very interesting clinical collaboration with Karolinska Institute. Professors Matthias Löhr and Lennart Eriksson will test for the...
iCellate announces a new clinical collaboration with MD, PhD Peter Cashin at Akademiska Hospital in Uppsala, who will evaluate the clinical relevance of measuring levels of...
The structure in iCellate®’s operational leadership and ownership has changed. Pelle Redare and Iohn Ryott have joined the company and act as both co-owners, members of the...
Icellate received a grant from Uppsala Bio, the Bio-X grant
New grant: Intellectual Property Right (IPR) strategy grant from the Swedish Incubators and Science Parks (SISP)
Icellate received an Intellectual Property Right (IPR) strategy grant from the Swedish Incubators and Science Parks
Uppsala BIO has signed a new agreement with the global pharmaceutical and diagnostics company Roche to support Icellate, a new BIO-X project. The project aims to evaluate a...